MCID: SQM013
MIFTS: 79

Squamous Cell Carcinoma, Head and Neck

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

MalaCards integrated aliases for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 53 13
Squamous Cell Carcinoma of the Head and Neck 37 12 49 24 71 28 69
Hnscc 53 49 24 55 71 51
Head and Neck Squamous Cell Carcinoma 12 49 24 55 14
Carcinoma, Squamous Cell of Head and Neck 72 49 41
Head and Neck Cancer 49 40
Squamous Cell Carcinoma, Head and Neck, Somatic 53
Squamous Cell Carcinomas of Head and Neck 12
Squamous Cell Carcinoma of Head and Neck 55
Carcinoma of the Head and Neck 12
Cancer of Head and Neck 69
Scchn 24

Characteristics:

Orphanet epidemiological data:

55
squamous cell carcinoma of head and neck
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages;

OMIM:

53
Inheritance:
autosomal recessive


HPO:

31
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 53 275355
Disease Ontology 12 DOID:5520
NCIt 46 C34447
Orphanet 55 ORPHA67037
MESH via Orphanet 42 C535575
UMLS via Orphanet 70 C1168401
MedGen 39 C1168401
SNOMED-CT via HPO 65 258211005 28899001 402815007

Summaries for Squamous Cell Carcinoma, Head and Neck

MedlinePlus : 40 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to tongue cancer and thyroid cancer, and has symptoms including squamous cell carcinoma, equilibration disorder and vertigo/dizziness. An important gene associated with Squamous Cell Carcinoma, Head and Neck is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Erbitux and Ethyol have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and salivary gland, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Genetics Home Reference : 24 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

NIH Rare Diseases : 49 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments. Last updated: 8/3/2015

UniProtKB/Swiss-Prot : 71 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Wikipedia : 72 Squamous cell carcinomas, also known as epidermoid carcinoma are a number of different types of cancer... more...

Description from OMIM: 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 tongue cancer 33.0 CCND1 CDH1 CDKN2A MMP2 MMP9 TP53
2 thyroid cancer 32.9 CCND1 CDH1 HRAS PTEN TP53
3 oral cancer 32.8 CCND1 CDH1 CDKN2A EGFR FHIT MMP2
4 salivary gland cancer 32.5 EGFR MMP2 MMP9 PTEN STAT3
5 papilloma 31.6 CCND1 CDKN2A PTEN TP53
6 squamous cell carcinoma 31.0 CCND1 CD44 CDH1 CDKN2A CTTN EGFR
7 oral squamous cell carcinoma 30.6 CCND1 CD44 CDH1 CDKN2A CTTN EGFR
8 spitz nevus 10.9 CDKN2A HRAS TP53
9 salivary gland cancer, adult 10.9
10 squamous cell carcinoma of the larynx 10.9 CDKN2A EGFR TP53
11 synchronous bilateral breast carcinoma 10.9 CCND1 PTEN TP53
12 nasal cavity adenocarcinoma 10.9 CDKN2A HRAS TP53
13 gastric adenosquamous carcinoma 10.9 CD44 CDKN2A EGFR
14 skin carcinoma in situ 10.9 CCND1 CDKN2A STAT3
15 bladder squamous cell carcinoma 10.8 CDKN2A PTEN TP53
16 ethmoid sinus cancer 10.8 CCND1 CTTN EGFR HRAS
17 meningeal melanomatosis 10.8 CDKN2A HRAS TP53
18 ethmoid sinus adenocarcinoma 10.8 CCND1 CTTN EGFR HRAS
19 gliomatosis cerebri 10.8 EGFR PTEN TP53
20 villous adenocarcinoma 10.8 EGFR MMP2 MMP9
21 balanitis xerotica obliterans 10.8 CCND1 CDKN2A TP53
22 esophagus squamous cell carcinoma 10.8 CCND1 CDH1 CTTN
23 megaesophagus 10.8 CDKN2A FHIT TP53
24 oropharynx cancer 10.8 CDKN2A EGFR TP53
25 melanoma, cutaneous malignant 1 10.8 CDKN2A HRAS PTEN TP53
26 cell type benign neoplasm 10.8 CCND1 CDKN2A HRAS TP53
27 cervix uteri carcinoma in situ 10.8 CDKN2A FHIT TP53
28 bone squamous cell carcinoma 10.8 CDKN2A CTTN STAT3 TP53
29 biliary tract neoplasm 10.8 CDKN2A HRAS TP53
30 uterine carcinosarcoma 10.8 EGFR HRAS TP53
31 li-fraumeni syndrome 10.8 CDKN2A EGFR PTEN TP53
32 basaloid squamous cell carcinoma 10.8 CDKN2A EGFR TP53
33 soft tissue sarcoma 10.8 EGFR TP53 VEGFA
34 suppressor of tumorigenicity 3 10.8 CDKN2A FHIT TP53
35 intestinal benign neoplasm 10.8 CCND1 CDH1 HRAS TP53
36 salivary gland adenoid cystic carcinoma 10.8 CCND1 CDH1 CTTN HRAS
37 clear cell renal cell carcinoma 10.8 CCND1 EGFR TP53 VEGFA
38 in situ carcinoma 10.8 CDH1 CDKN2A EGFR TP53
39 hidradenocarcinoma 10.8 CCND1 EGFR TP53
40 penile cancer 10.8 CCND1 CDKN2A EGFR HRAS TP53
41 oligodendroglioma 10.8 CDKN2A EGFR PTEN TP53
42 cervical squamous cell carcinoma 10.8 CDH1 CDKN2A EGFR TP53
43 vulva cancer 10.8 CDKN2A EGFR TP53
44 geographic tongue 10.8 EGFR TNFRSF10B VEGFA
45 ductal carcinoma in situ 10.8 CCND1 CDH1 EGFR TP53
46 primary peritoneal carcinoma 10.8 EGFR TP53 VEGFA
47 endocrine gland cancer 10.8 CDH1 CDKN2A HRAS TP53
48 endometrial adenocarcinoma 10.8 CDKN2A EGFR PTEN TP53 VEGFA
49 adenomyosis 10.8 MMP2 MMP9 VEGFA
50 mucinous adenocarcinoma 10.8 CDKN2A EGFR TP53

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

Symptoms via clinical synopsis from OMIM:

53
Lab:
beta family transforming growth factor resistance


Clinical features from OMIM:

275355

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

31
# Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 31 HP:0002860

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


equilibration disorder, vertigo/dizziness, sore throat, tinnitus, snoring, halitosis, coughing

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 CCND1 CD44 CDH1 CDKN2A HRAS ING1
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CD44 EGFR HRAS PTEN VEGFA

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

43 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.47 CCND1 CD44 CDH1 CDKN2A CTTN CXCL14
2 cardiovascular system MP:0005385 10.45 CCND1 CD44 CDH1 CDKN2A CTTN EGFR
3 homeostasis/metabolism MP:0005376 10.45 CCND1 CD44 CDH1 CDKN2A CXCL14 EGFR
4 mortality/aging MP:0010768 10.42 ING1 MAP2K2 MMP2 MMP9 PTEN STAT3
5 cellular MP:0005384 10.41 VEGFA ING1 MAP2K2 MMP9 PTEN STAT3
6 immune system MP:0005387 10.41 CXCL14 EGFR FHIT ING1 MMP2 MMP9
7 digestive/alimentary MP:0005381 10.4 FHIT HRAS MAP2K2 MMP9 PTEN STAT3
8 hematopoietic system MP:0005397 10.4 CDKN2A CTTN CXCL14 EGFR FHIT ING1
9 behavior/neurological MP:0005386 10.39 CCND1 CD44 CDKN2A CXCL14 HRAS ING1
10 endocrine/exocrine gland MP:0005379 10.35 TP53 VEGFA CCND1 CD44 CDH1 CDKN2A
11 integument MP:0010771 10.34 MMP9 PTEN STAT3 TP53 VEGFA CCND1
12 neoplasm MP:0002006 10.33 CCND1 CD44 CDH1 CDKN2A EGFR FHIT
13 craniofacial MP:0005382 10.19 CCND1 EGFR HRAS MAP2K2 MMP2 STAT3
14 nervous system MP:0003631 10.17 CCND1 CD44 CDKN2A EGFR HRAS MMP2
15 muscle MP:0005369 10.13 EGFR MMP2 MMP9 PTEN STAT3 TP53
16 liver/biliary system MP:0005370 10.11 CDKN2A CXCL14 EGFR PTEN STAT3 TP53
17 normal MP:0002873 10.11 CCND1 CD44 CDH1 EGFR HRAS MAP2K2
18 reproductive system MP:0005389 10.03 EGFR MMP9 PTEN STAT3 TP53 VEGFA
19 no phenotypic analysis MP:0003012 10.01 CDH1 CDKN2A CTTN CXCL14 EGFR HRAS
20 renal/urinary system MP:0005367 9.97 CD44 CXCL14 EGFR HRAS MMP9 PTEN
21 respiratory system MP:0005388 9.93 CCND1 CD44 CDKN2A CTTN EGFR HRAS
22 skeleton MP:0005390 9.73 CCND1 CD44 CDKN2A EGFR HRAS MAP2K2
23 vision/eye MP:0005391 9.36 CCND1 CD44 CDKN2A EGFR MAP2K2 MMP2

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erbitux 17 45 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Ethyol 17 AMIFOSTINE Alza December 8, 1995
3
Taxotere 17 45 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
4
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
5
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124 9877265
6 Alkylating Agents Phase 4,Phase 2,Phase 1
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
9 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Mitomycins Phase 4,Phase 2
13 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
17
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
18
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
19
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
20 Racepinephrine Approved Phase 3,Phase 2 329-65-7
21
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
24
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
25
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
26
Indomethacin Approved, Investigational Phase 3,Phase 2,Phase 1 53-86-1 3715
27
Zinc Approved, Investigational Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
28
nivolumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
29
Vinblastine Approved Phase 3 865-21-4 241903 13342
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
31
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
32
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538
33 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
34
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
35
Tremelimumab Investigational Phase 3,Phase 1,Phase 2 745013-59-6
36 Nimorazole Investigational Phase 3,Phase 2 6506-37-2
37 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
38 Anesthetics Phase 3
39 Angiogenesis Inhibitors Phase 3,Phase 1,Phase 2
40 Angiogenesis Modulating Agents Phase 3,Phase 1,Phase 2
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
42 Endostatins Phase 3,Phase 2 71581480
43
s 1 (combination) Phase 3
44 Adrenergic Agents Phase 3,Phase 2
45 Adrenergic Agonists Phase 3,Phase 2
46 Adrenergic alpha-Agonists Phase 3,Phase 2
47 Adrenergic beta-Agonists Phase 3,Phase 2
48 Anti-Asthmatic Agents Phase 3,Phase 2
49 Autonomic Agents Phase 3,Phase 2,Phase 1
50 Bronchodilator Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 490)

# Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
3 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4 Nolbaxol;Taxotere;cisplatin
4 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
6 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
7 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
8 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
9 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
10 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
11 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
12 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
13 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3 Erlotinib chlorhydrate;Cisplatin
14 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
15 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Completed NCT00206219 Phase 3 Gefitinib;methotrexate
16 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
17 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed NCT01177956 Phase 3 Cisplatin;5-Fluorouracil
18 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
19 Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial Completed NCT00995293 Phase 3 DOCETAXEL;CISPLATIN;5-FLUOROURACIL
20 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Completed NCT00122460 Phase 3 Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
21 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Completed NCT00496652 Phase 3 Zalutumumab
22 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00460265 Phase 3 ARM 2;ARM 1
23 Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT00401323 Phase 2, Phase 3 docetaxel (XRP6976);cisplatin;5-fluorouracil (5-FU)
24 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
25 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
26 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
27 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
28 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
29 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
30 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed NCT00424255 Phase 3 Lapatinib
31 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
32 Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer Completed NCT00273546 Phase 3 XRP6976 (Docetaxel/Taxotere)
33 Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer Completed NCT03370367 Phase 3 13-cis retinoic acid
34 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Completed NCT01265849 Phase 3
35 Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) Recruiting NCT03342352 Phase 3 Nivolumab;Epacadostat;Placebo;Carboplatin;Cisplatin;Cetuximab;5-Fluorouracil
36 Changes in Body Composition After EPA Supplementation in Head and Neck Patients Recruiting NCT02715596 Phase 3
37 Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Recruiting NCT02952586 Phase 3 Avelumab
38 Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck Recruiting NCT01427478 Phase 3 AFATINIB;Placebo of AFATINIB
39 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Recruiting NCT03349710 Phase 3 Placebo;Cisplatin
40 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02741570 Phase 3 Cetuximab/Erbitux;Cisplatin/Platinol;Carboplatin/Paraplatin;Fluorouracil/Adrucil
41 Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial Recruiting NCT02765503 Phase 3
42 Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) Recruiting NCT02999087 Phase 3 Cetuximab;avelumab;Cisplatin
43 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
44 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Recruiting NCT02661152 Phase 3 Nimorazole
45 Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer Recruiting NCT01772706 Phase 3
46 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
47 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Active, not recruiting NCT02105636 Phase 3 Nivolumab;Cetuximab;Methotrexate;Docetaxel
48 Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
49 Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Active, not recruiting NCT00999700 Phase 3 docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin
50 Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Subjects With Head and Neck Cancer Active, not recruiting NCT02383966 Phase 3 Cetuximab;Cisplatin/Carboplatin;5-fluorouracil

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Cochrane evidence based reviews: carcinoma, squamous cell of head and neck

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 28 ING1 PTEN TNFRSF10B

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

38
Skin, Lung, Salivary Gland, Testes, Lymph Node, Prostate, Liver

Publications for Squamous Cell Carcinoma, Head and Neck

Articles related to Squamous Cell Carcinoma, Head and Neck:

(show top 50) (show all 811)
# Title Authors Year
1
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. ( 28950305 )
2017
2
GTSP1 expression in non-smoker and non-drinker patients with squamous cell carcinoma of the head and neck. ( 28817620 )
2017
3
Mild pulmonary emphysema a risk factor for interstitial lung disease when using cetuximab for squamous cell carcinoma of the head and neck. ( 28741444 )
2017
4
Basaloid Squamous Cell Carcinoma of the Head and Neck: Subclassification into Basal, Ductal, and Mixed Subtypes Based on Comparison of Clinico-pathologic Features and Expression of p53, Cyclin D1, Epidermal Growth Factor Receptor, p16, and Human Papillomavirus. ( 28593937 )
2017
5
Relative expression of vascular endothelial growth factor isoforms in squamous cell carcinoma of the head and neck. ( 25521093 )
2016
6
Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. ( 26858129 )
2016
7
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. ( 26712222 )
2016
8
Influence of Photodynamic Therapy on the Expression of Cancer/Testis Antigens in Squamous Cell Carcinoma of the Head and Neck. ( 27466502 )
2016
9
Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment. ( 27322955 )
2016
10
Expression of the extracellular sulfatase SULF2 is associated with squamous cell carcinoma of the head and neck. ( 27223083 )
2016
11
Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck. ( 27802455 )
2016
12
A Limited Immunohistochemical Panel to Distinguish Basal Cell Carcinoma of Cutaneous Origin From Basaloid Squamous Cell Carcinoma of the Head and Neck. ( 27438511 )
2016
13
Variants of EVER1 and EVER2 (TMC6 and TMC8) and human papillomavirus status in patients with mucosal squamous cell carcinoma of the head and neck. ( 27097911 )
2016
14
A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. ( 26711789 )
2016
15
A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. ( 25680594 )
2015
16
Wilms' tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck. ( 25929687 )
2015
17
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. ( 25659884 )
2015
18
Nano-Quadrapeutics rapidly detects and destroys squamous cell carcinoma of the head and neck. ( 25677387 )
2015
19
[(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial. ( 25670018 )
2015
20
Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck. ( 25878965 )
2015
21
DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. ( 26001739 )
2015
22
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. ( 25876000 )
2015
23
Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. ( 25623438 )
2015
24
Chemokine receptor 7 promotes tumor migration and invasiveness via the RhoA/ROCK pathway in metastatic squamous cell carcinoma of the head and neck. ( 25434638 )
2015
25
Prognostic value of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. ( 25895596 )
2015
26
Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. ( 25810697 )
2015
27
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. ( 25333206 )
2015
28
Phase 2 Study of Docetaxel, Cisplatin, and Concurrent Radiation for Technically Resectable Stage III-IV Squamous Cell Carcinoma of the Head and Neck. ( 25832686 )
2015
29
Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. ( 26483987 )
2015
30
Human papillomavirus status and p16(INK4A) expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia. ( 25677091 )
2015
31
Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. ( 25670542 )
2015
32
Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck. ( 25868613 )
2015
33
Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). ( 25725588 )
2015
34
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. ( 25639864 )
2015
35
Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). ( 25671770 )
2015
36
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. ( 25892145 )
2015
37
The role of Pyk2 in the CCR7-mediated regulation of metastasis and viability in squamous cell carcinoma of the head and neck cells in vivo and in vitro. ( 26352169 )
2015
38
HPV-related squamous cell carcinoma of the head and neck: An update on testing in routine pathology practice. ( 25724476 )
2015
39
Metadherin regulation of vascular endothelial growth factor expression is dependent upon the PI3K/Akt pathway in squamous cell carcinoma of the head and neck. ( 25674742 )
2015
40
Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck : A retrospective single center analysis. ( 24413895 )
2014
41
Chemoradiotherapy is superior to radiotherapy alone after surgery in advanced squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. ( 25356100 )
2014
42
Fibroblast growth factorA 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck. ( 23861152 )
2014
43
Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. ( 25037161 )
2014
44
CCR7 Regulates Cell Migration and Invasion through JAK2/STAT3 in Metastatic Squamous Cell Carcinoma of the Head and Neck. ( 25405202 )
2014
45
Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival. ( 25043982 )
2014
46
Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related. ( 25042603 )
2014
47
Non-Muscle Myosin IIa Heavy Chain Links Squamous-Cell Carcinoma of the Head and Neck to the DNA Damage Response. ( 25202680 )
2014
48
Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional centre. ( 24995842 )
2014
49
Elevated expression of T-lymphoma invasion and metastasis inducing factor 1 in squamous-cell carcinoma of the head and neck and its clinical significance. ( 24189000 )
2014
50
A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. ( 25081631 )
2014

Variations for Squamous Cell Carcinoma, Head and Neck

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

71
# Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6 (show top 50) (show all 293)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
2 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh37 Chromosome 10, 89692878: 89692878
3 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh37 Chromosome 13, 111372083: 111372083
4 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh37 Chromosome 13, 111372086: 111372086
5 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh37 Chromosome 13, 111372014: 111372014
6 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
7 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
8 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
9 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
10 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
11 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
13 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
14 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
17 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
18 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
19 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
20 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
21 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
22 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
23 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
24 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
25 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
26 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
27 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
28 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
29 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
30 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
31 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
32 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
33 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
34 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
35 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
36 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
37 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
38 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
39 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
40 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
41 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
42 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
43 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
44 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
45 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
46 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
47 EGFR NM_005228.4(EGFR): c.2155G> C (p.Gly719Arg) single nucleotide variant Likely pathogenic,drug response rs28929495 GRCh37 Chromosome 7, 55241707: 55241707
48 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
49 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289
50 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh37 Chromosome 9, 21971017: 21971017

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9 (show top 50) (show all 589)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM17483 PTCH1 skin,neck,carcinoma,NS c.1729-1G>T p.? 52
2 COSM17468 PTCH1 skin,neck,carcinoma,NS c.584G>T p.R195M 52
3 COSM29053 PTCH1 skin,neck,carcinoma,NS c.833G>A p.W278* 52
4 COSM29072 PTCH1 skin,neck,carcinoma,NS c.1067+1G>A p.? 52
5 COSM14452 PTCH1 skin,neck,carcinoma,NS c.2321G>A p.G774E 52
6 COSM516 KRAS skin,neck,carcinoma,NS c.34G>T p.G12C 52
7 COSM498 HRAS skin,neck,carcinoma,squamous cell carcinoma BRAF inhibitor related c.182A>T p.Q61L 52
8 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 41
9 COSM11181 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.764T>C p.I255T 41
10 COSM43565 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.857A>G p.E286G 41
11 COSM43695 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.748C>T p.P250S 41
12 COSM10786 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.949C>T p.Q317* 41
13 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 41
14 COSM43592 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.395A>T p.K132M 41
15 COSM45615 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.776A>G p.D259G 41
16 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 41
17 COSM11133 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>C p.C242S 41
18 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 41
19 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 41
20 COSM45248 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.805A>T p.S269C 41
21 COSM10727 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.438G>A p.W146* 41
22 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 41
23 COSM10988 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.772G>A p.E258K 41
24 COSM43635 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>T p.H179L 41
25 COSM44350 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.699C>G p.H233Q 41
26 COSM11063 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>T p.M237I 41
27 COSM11677 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.925C>T p.P309S 41
28 COSM11166 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 41
29 COSM10859 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>T p.V272L 41
30 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 41
31 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 41
32 COSM44821 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.412G>A p.A138T 41
33 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 41
34 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 41
35 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 41
36 COSM45636 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.934A>T p.T312S 41
37 COSM11066 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.578A>T p.H193L 41
38 COSM43564 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.708C>A p.Y236* 41
39 COSM10992 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>G p.R282G 41
40 COSM10768 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.535C>T p.H179Y 41
41 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 41
42 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 41
43 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 41
44 COSM10812 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.722C>T p.S241F 41
45 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 41
46 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 41
47 COSM45794 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.421T>G p.C141G 41
48 COSM44233 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.840A>C p.R280S 41
49 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 41
50 COSM10738 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.542G>A p.R181H 41

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification EVI1 head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MDS1 head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion DLEC head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplific ation EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain FAK head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma
42 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma

Expression for Squamous Cell Carcinoma, Head and Neck

LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane protease, serine 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine-rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T-cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin, beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17, type I Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4, type II Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone-like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1, interferon-inducible Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for Squamous Cell Carcinoma, Head and Neck

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 CCND1 CDH1 CTTN EGFR HRAS MAP2K2
2
Show member pathways
14.14 CCND1 CD44 CDH1 EGFR HRAS MAP2K2
3
Show member pathways
13.89 CCND1 CDH1 CDKN2A CXCL14 EGFR HRAS
4
Show member pathways
13.82 CCND1 CDKN2A EGFR HRAS MAP2K2 MMP2
5
Show member pathways
13.51 CCND1 CXCL14 EGFR HRAS PTEN STAT3
6
Show member pathways
13.43 EGFR HRAS MAP2K2 MMP2 MMP9 PTEN
7
Show member pathways
13.43 CCND1 CD44 EGFR HRAS MAP2K2 MMP2
8
Show member pathways
13.3 CCND1 EGFR HRAS MAP2K2 PTEN STAT3
9
Show member pathways
13.12 CDKN2A EGFR HRAS MAP2K2 MMP9 VEGFA
10
Show member pathways
13.08 CDH1 HRAS MAP2K2 STAT3 TP53 VEGFA
11
Show member pathways
13.07 CCND1 EGFR HRAS MAP2K2 PTEN TP53
12
Show member pathways
13.03 CCND1 CDH1 CDKN2A EGFR FHIT HRAS
13
Show member pathways
13 EGFR HRAS MAP2K2 PTEN STAT3 VEGFA
14
Show member pathways
12.99 CCND1 EGFR HRAS MAP2K2 PTEN STAT3
15
Show member pathways
12.88 CDKN2A HRAS MAP2K2 TNFRSF10B TP53
16
Show member pathways
12.87 CCND1 MAP2K2 STAT3 TNFRSF10B TP53
17
Show member pathways
12.86 CCND1 HRAS MAP2K2 PTEN STAT3
18
Show member pathways
12.85 CCND1 CDH1 CDKN2A EGFR HRAS MAP2K2
19 12.84 EGFR HRAS MAP2K2 TP53 VEGFA
20
Show member pathways
12.81 CDH1 EGFR HRAS MAP2K2 VEGFA
21
Show member pathways
12.81 CDH1 HRAS MAP2K2 PTEN STAT3 TP53
22
Show member pathways
12.76 EGFR HRAS MAP2K2 STAT3 TP53
23 12.76 CCND1 CDH1 CDKN2A EGFR HRAS MAP2K2
24
Show member pathways
12.74 CCND1 EGFR HRAS MAP2K2 MMP2 PTEN
25
Show member pathways
12.68 EGFR HRAS MMP2 STAT3 TP53
26
Show member pathways
12.64 CCND1 HRAS MAP2K2 MMP9 PTEN STAT3
27
Show member pathways
12.63 CCND1 CDKN2A EGFR HRAS MAP2K2 MMP2
28
Show member pathways
12.6 EGFR HRAS MAP2K2 PTEN TP53
29
Show member pathways
12.59 CDH1 EGFR HRAS MAP2K2 STAT3 TP53
30
Show member pathways
12.58 CCND1 HRAS MAP2K2 PTEN STAT3
31
Show member pathways
12.58 CCND1 EGFR HRAS MAP2K2 STAT3 TP53
32
Show member pathways
12.5 CD44 HRAS MAP2K2 STAT3 VEGFA
33
Show member pathways
12.49 CCND1 HRAS MAP2K2 PTEN STAT3 TP53
34
Show member pathways
12.47 CCND1 CDKN2A PTEN TNFRSF10B TP53
35
Show member pathways
12.45 CD44 HRAS MAP2K2 STAT3
36
Show member pathways
12.45 EGFR HRAS MAP2K2 VEGFA
37
Show member pathways
12.45 CCND1 EGFR HRAS STAT3
38 12.44 CCND1 CDH1 CDKN2A TP53
39
Show member pathways
12.41 CCND1 HRAS MAP2K2 STAT3
40
Show member pathways
12.4 CCND1 EGFR HRAS MAP2K2
41 12.4 CCND1 CDKN2A HRAS STAT3 TP53
42 12.37 CCND1 CD44 CDKN2A EGFR HRAS MAP2K2
43
Show member pathways
12.36 HRAS MAP2K2 STAT3 TP53 VEGFA
44
Show member pathways
12.34 CCND1 PTEN TNFRSF10B TP53
45
Show member pathways
12.33 EGFR HRAS MAP2K2 PTEN VEGFA
46
Show member pathways
12.32 CCND1 EGFR HRAS MAP2K2 PTEN TP53
47 12.29 CCND1 CDKN2A HRAS MAP2K2 PTEN TP53
48 12.28 EGFR HRAS MAP2K2 PTEN STAT3
49
Show member pathways
12.27 HRAS MAP2K2 PTEN STAT3
50 12.27 CCND1 CDH1 EGFR PTEN TP53 VEGFA

GO Terms for Squamous Cell Carcinoma, Head and Neck

Cellular components related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi apparatus GO:0005794 9.5 CD44 CDH1 CTTN CXCL14 EGFR HRAS
2 cytoplasmic side of plasma membrane GO:0009898 8.8 CDH1 MAP2K2 PTEN

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 CDKN2A ING3 MMP9 PTEN TP53
2 response to drug GO:0042493 9.96 CCND1 CDH1 PTEN STAT3 TP53
3 negative regulation of cell proliferation GO:0008285 9.95 CDKN2A HRAS ING1 PTEN STAT3 TP53
4 leukocyte migration GO:0050900 9.91 CD44 HRAS MMP9 TNFRSF10B
5 positive regulation of gene expression GO:0010628 9.91 CDKN2A HRAS PTEN STAT3 TP53 VEGFA
6 positive regulation of cell migration GO:0030335 9.88 EGFR HRAS MMP9 VEGFA
7 ephrin receptor signaling pathway GO:0048013 9.83 HRAS MMP2 MMP9
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.82 CD44 TP53 VEGFA
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 CD44 EGFR VEGFA
10 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.81 CD44 TNFRSF10B VEGFA
11 response to ethanol GO:0045471 9.81 CCND1 PTEN STAT3 TP53
12 response to estradiol GO:0032355 9.8 CCND1 EGFR PTEN STAT3
13 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 CD44 EGFR HRAS MAP2K2 PTEN
14 cell proliferation GO:0008283 9.8 EGFR HRAS PTEN RPS27 STAT3 TP53
15 positive regulation of transcription, DNA-templated GO:0045893 9.8 CDH1 CDKN2A EGFR ING1 MAP2K2 STAT3
16 Ras protein signal transduction GO:0007265 9.79 CDKN2A HRAS TP53
17 positive regulation of epithelial cell proliferation GO:0050679 9.77 EGFR HRAS VEGFA
18 positive regulation of MAP kinase activity GO:0043406 9.77 EGFR HRAS VEGFA
19 response to organic substance GO:0010033 9.76 CCND1 CDH1 PTEN STAT3
20 cellular response to reactive oxygen species GO:0034614 9.71 EGFR MMP9 TP53
21 extracellular matrix disassembly GO:0022617 9.67 CD44 CDH1 MMP2 MMP9
22 response to leptin GO:0044321 9.63 CCND1 STAT3
23 cellular response to leptin stimulus GO:0044320 9.63 PTEN STAT3
24 mitotic G1 DNA damage checkpoint GO:0031571 9.62 CCND1 TP53
25 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 EGFR MAP2K2
26 positive regulation of protein phosphorylation GO:0001934 9.55 CCND1 EGFR HRAS MMP9 VEGFA
27 response to UV-A GO:0070141 9.52 CCND1 EGFR
28 negative regulation of apoptotic process GO:0043066 9.5 CD44 EGFR MMP9 PTEN STAT3 TP53
29 response to organic cyclic compound GO:0014070 9.02 CCND1 EGFR PTEN STAT3 TP53
30 apoptotic process GO:0006915 10.05 CDKN2A FHIT HRAS PTEN TNFRSF10B TP53
31 positive regulation of cell proliferation GO:0008284 10.02 CCND1 EGFR HRAS PTEN STAT3 VEGFA

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 CDH1 EGFR FHIT MMP9 PTEN STAT3
2 protein binding GO:0005515 9.62 CCND1 CD44 CDH1 CDKN2A CTTN CXCL14
3 protein phosphatase binding GO:0019903 9.43 EGFR STAT3 TP53
4 protein kinase binding GO:0019901 9.43 CCND1 CDKN2A EGFR PTEN STAT3 TP53

Sources for Squamous Cell Carcinoma, Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....